Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

31.73 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 24, 2024

Via Benzinga

Quince Therapeutics to Participate at Upcoming Investor Conferences

October 14, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 03, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

August 19, 2024

Via Benzinga

Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket ↗

August 16, 2024

Via Benzinga

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

August 15, 2024

From Quince Therapeutics, Inc.

Via Business Wire

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 ↗

August 13, 2024

Quince Therapeutics just reported results for the second quarter of 2024.

Via InvestorPlace

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

August 13, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

June 25, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

June 03, 2024

From Quince Therapeutics, Inc.

Via Business Wire

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024 ↗

May 13, 2024

Quince Therapeutics just reported results for the first quarter of 2024.

Via InvestorPlace

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

May 06, 2024

From Quince Therapeutics, Inc.

Via Business Wire

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 ↗

April 02, 2024

Quince Therapeutics just reported results for the fourth quarter of 2023.

Via InvestorPlace

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

April 01, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Launches Scientific Advisory Board

February 22, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

February 15, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 07, 2024

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics to Participate at Investor Events in January 2024

January 04, 2024

From Quince Therapeutics, Inc.

Via Business Wire

SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying ↗

December 08, 2023

The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗

December 04, 2023

The Dow Jones closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

October 23, 2023

From Quince Therapeutics, Inc.

Via Business Wire

Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket ↗

September 29, 2023

Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading.

Via Benzinga

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

September 28, 2023

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

September 06, 2023

From Quince Therapeutics, Inc.

Via Business Wire

Quince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying ↗

August 14, 2023

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

August 10, 2023

From Quince Therapeutics, Inc.

Via Business Wire

What's Going On With Quince Therapeutics Stock Today ↗

July 24, 2023

Quince Therapeutics Inc (NASDAQ: QNCX) has agreed to acquire EryDel SpA, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream

Via Benzinga

Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 24, 2023

Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.

Via Benzinga

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

July 24, 2023

From Quince Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.